Inhibikase Therapeutics Inc (IKT) — Titan Protect Analysis

IKT

Inhibikase Therapeutics Inc

Healthcare · ·

$1.63

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$221M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-4.29

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-40.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.00

+268% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 7 analysts covering this stock

About Inhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to im

https://www.inhibikase.com

Country: United States Employees: 35 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.414

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0017

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.032

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-2.1%

Historical annualised return based on price data

Max Drawdown

-64.5%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

109

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.96

Less volatile than the market — more defensive

52W High

$2.26

28% below the year high

52W Low

$1.33

23% above the year low

Avg Volume

1,149,247

Average daily shares traded — higher means easier to buy and sell

Short Ratio

20.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.44

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-14,962,229

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-50,961,296

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$8.00

Target Median

$6.00

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go